OTC Pink Basic Disclosure Guidelines

1) Name of the issuer and its predecessors (if any)

In answering this item, please also provide any names used by predecessor entities in the past five years and the dates of the name changes.

Current Name: Predictive Technology Group, Inc. – 07/16/2015

Former Name: Global Enterprises Group, Inc.-03/12/2014

Former Name: GLOBAL Housing Group -04/20/2010

2) Address of the issuer's principal executive offices

Company Headquarters
Address 1: **2749 East Parleys Way, Suite 101**
Address 2: **Salt Lake City, UT 84109**
Address 3: Phone: **7573066090**
Email: **info@predictivetechnologygroup.com**
Website(s): **www.predictivertechnologygroup.com**

IR Contact
Address 1: **YES INTERNATIONAL**
Address 2: **3419 Virginia Beach Blvd, Unit 252**
Address 3: **Virginia Beach, VA 23452**
Phone: **7573066090**
Email: **rich@yesinternational.com**
Website(s): **www.yesinternational.com**

3) Security Information

Trading Symbol: **PRED**
Exact title and class of securities outstanding: **900,000,000 shares Common Stock; par value $0.001**
10,000,000 shares Preferred par value $0.001
CUSIP: 74039H102
Par or Stated Value: 0.001 Common
Total shares authorized: 900,000,000 as of: August 31, 2016
Total shares outstanding: 166,193,598 as of: August 31, 2016

Additional class of securities (if necessary):
Trading Symbol: N/A
Exact title and class of securities outstanding: 10,000,000 shares preferred par value $0.001
CUSIP: none
Par or Stated Value: .001
Total shares authorized: 10,000,000 as of: August 31, 2016
Total shares outstanding: -0- as of: August 31, 2016

Transfer Agent
Name: **Transfer Online, Inc.**

Address 1: **512 SE Salmon Street**

Address 2: **Portland, OR 97214**

Address 3: **www.transferonline.com**

Phone: **Phone #503-227-2950**

Is the Transfer Agent registered under the Exchange Act?* Yes: ☒ No: ☐

*To be included in the OTC Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

List any restrictions on the transfer of security:

NONE

Describe any trading suspension orders issued by the SEC in the past 12 months.

NONE

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

Name change only, NO recapitization of the Company, changed name to PREDICTIVE TEHCNOLOGY GROUP, INC. on July 16, 2015

Predictive Technology Group, Inc. on April 15, 2015 announces the Company has entered into an agreement to acquire a majority position of Predictive Therapeutics, LLC. On February 16, 2016 the Company acquired the remaining 16% of Predictive Therapeutics, LLC which is now a wholly owned subsidiary of the PRED. for 2,500,000 shares of restricted Rule 144 shares, These shares have yet to be issued but the pending share exchange has been added to the outstanding share count.

On January 26, 2016 the Company announced the acquisition of LifeCode Genetics, Inc. as a wholly owned subsidiary.

On February 16, 2016 the Company announced the acquisition of the remaining outstanding shares in Predictive Therapeutics, LLC.

On April 12, 2016 the Company announces finalization of the acquisition of ReNovo Biotech, Inc. for 8,500,000 shares of restricted Rule 144 shares, These shares have yet to be issued but the pending share exchange has been added to the outstanding share count.

4) Issuance History

List below any events, in chronological order, that resulted in changes in total shares outstanding by the issuer in the past two fiscal years and any interim period. The list shall include all offerings of equity securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services, describing (1) the securities, (2) the persons or entities to whom such securities were issued and (3) the services provided by such persons or entities. The list shall indicate:

A. The nature of each offering (e.g., Securities Act Rule 504, intrastate, etc.);

None

B. Any jurisdictions where the offering was registered or qualified;

None

C. The number of shares offered;

None

D. The number of shares sold;

None

E. The price at which the shares were offered, and the amount actually paid to the issuer;

None

F. The trading status of the shares; and

N/A

G. Whether the certificates or other documents that evidence the shares contain a legend (1) stating that the shares have not been registered under the Securities Act and (2) setting forth or referring to the restrictions on transferability and sale of the shares under the Securities Act.

N/A

5) Financial Statements

Provide the financial statements described below for the most recent fiscal year end or quarter end to maintain qualification for the OTC Pink Current Information tier. For the initial disclosure statement (qualifying for Current Information for the first time) please provide reports for the two previous fiscal years and any interim periods.

A. Balance sheet;
B. Statement of income;
C. Statement of cash flows;
D. Financial notes; and
E. Audit letter, if audited

The financial statements requested pursuant to this item shall be prepared in accordance with US GAAP by persons with sufficient financial skills.

You may either (i) attach/append the financial statements to this disclosure statement or (ii) post such financial statements through the OTC Disclosure & News Service as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial reports separately as described in part (ii) above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to otciq.com in the field below.

Quarterly Report Financial Statements for period ending August 31, 2016 are incorporated as reference and filed on OTC MARKETS' OTCIQ.COM on December 13, 2016.

Information contained in a Financial Report is considered current until the due date for the subsequent Financial Report. To remain in the OTC Pink Current Information tier, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of its fiscal quarter-end date.

6) Describe the Issuer's Business, Products and Services

Describe the issuer's business so a potential investor can clearly understand the company. In answering this item, please include the following:

A. a description of the issuer's business operations;

Predictive Technology Group, Inc., a publicly traded entity with stock symbol, PRED which traded on the OTC, looks to improve lives by indentifying, developing, acquiring and commercializing medical apparatuses and treatments that address human medical needs.

Predictive Technology Group, Inc., through its wholly owned subsidiaries, Predictive Therapeutics ("PRx") and Predictive Biotech, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics.

PRx has developed and/or acquired a number of proprietary technologies that open a window into the origin of human disease and the role that genes and their related proteins play in the disease's onset and progression.

PRx uses this information as the cornerstone in the development of new diagnostics that assess a person's risk of disease and therapeutic products designed to effectively prevent and/or treat the disease.

PRx' utilization of molecular diagnostics focuses on the analysis of genes and their mutations to assess a patient's inherited risk for developing a particular disease and its progression (predictive healthcare). Additionally, PRx believes that advances in the emerging field of molecular diagnostics will improve the ability to determine which patients are subject to a greater risk of developing disease and who therefore would benefit from preventive therapies. Molecular diagnostic products may also guide a patient's healthcare to ensure the patient receives the most appropriate treatment at the most appropriate time (i.e., most effective).

PRx is well positioned with short and long-term assets in its pipeline to be a leader in the future of preventative, personalized and precision healthcare. Current trends in medicine lie in the creation of new classes of drugs that treat the underlying cause, not just the symptoms, of disease and may be useful in disease prevention. By understanding the genetic basis of disease and by working with strategic partners, PRx believes that it will be able to develop drugs and treatment protocols that are more effective, resulting in better patient outcomes at significantly lower costs.

PRx' development expertise is uniquely enhanced by its strategic development collaborations. Some of those development assets are included below:

- **600,000 DNA samples in library as a result of a birth defect or serious maternity issue**
- **HIPAA compliant**
- **Collected from most genetically diverse population in U.S.**
- **Believed to be largest DNA library in world related to women's health**
- **Corresponding proprietary genealogy database developed from over 50,000 public sources**
- **Gen DB – Proprietary genealogy database used to accelerate genetic discoveries**

NHP-07 – First pharmaceutical/therapeutic candidate to be developed by PRx. Management believes NHP-07 with EndoRisk® as a companion diagnostic/prognostic is the only treatment protocol that can prevent development of

endometriosis and, in women experiencing advanced stages of endometriosis NHP-07, stop the progression of the disease while suppressing the debilitating symptoms.

-Approximately 7.5 million women suffer from endometriosis in the United States with only 2.5 million women currently diagnosed

Approximately 70 million women world wide are symptomatic of endometriosis
Greater than $1Billion annual US market

-Tremendous need for new more effective/lower side-effect therapeutics to meet this unmet demand

-Suppresses the symptoms of endometriosis in women diagnosed with endometriosis

-Prevents the development of the disease

-Combination of two or more existing FDA-approved compounds, whose safety has already been established over decades

-Coupled with EndoRisk® as a companion diagnostic NHP-07 can be given prior to development of endometriosis or becoming symptomatic to prevent the disease altogether

-Patent issued October, 2015 for combination of progesterone and NSAIDs (Non Steroidal Anti-Inflammatory Drugs)

-Patent issued October, 2015 for combination of progesterone and cannabinoids

Predictive Biotech develops and commercializes minimally manipulated allograft products through the isolation of a homogenous population of mesenchymal stromal/stem cells from umbilical cord and placental tissue and adults own tissue.

- **Corecyte® - Umbilical cord tissue stem cells are epigenetically young due to their source. In addition, the collection of umbilical cords is safe, non-invasive, and devoid of ethical concerns.**
- **Amniocyte® - Amniotic Allograft Suspension is a flowable tissue matrix allograft, derived from human placental amniotic fluid. It is used for minimally invasive treatment of damaged or inadequate tissue.**
- **Amniocyte® - Amniotic Allograft Membrane is composed of a complex extracellular matrix that is dehydrated and terminally sterilized with electron beam irradiation. Amniocyte allograft is a deceullurized dehydrated human amniotic membrane (ddHAM). It is derived from the placentas of normal, full term pregnancies.**
- **Amniocyte® - Adipose Autograft Kit allows patients to derive stem cells from their own tissues.**

Genetic diagnostics do not require approval by the FDA in order to go to market if the tests are Laboratory Developed Tests ("LDTs"), which are regulated under the Clinical Laboratory Improvement Amendments ("CLIA"). It is estimated that of the 2,000 genetic tests commercially available less than a dozen were reviewed by FDA. The American Clinical Laboratory Association ("ACLA") filed a citizen petition on June 4, 2013 challenging the FDA's authority to regulate LDTs as medical devices under the federal Food, Drug, and Cosmetic Act (FDCA). The ACLA stated, "CLIA allows laboratories the flexibility to develop and validate LDTs quickly to respond to public health needs." The ACLA also wrote, "Laboratories are able to update LDTs regularly as medicine advances, so that patients have access to the most advanced testing." LDTs are laboratory services, not products, and are not distributed, nor delivered or placed into market, noted the petition. "They are proprietary procedures for performing a diagnostic test using reagents and laboratory equipment, essentially know-how."

***Proven and Experienced Team* – An experienced team that has completed similar product ventures from conception to commercialization through internal sales and marketing and/or major strategic partnerships. The key executives have a track record of successfully developing and marketing high volume products in the healthcare field. As a result, PRED will be able to benefit from and leverage valuable relationships with industry leaders. Discussions have already commenced with significant companies that have major women's health franchises**.

Predictive Technology Group, Inc. through its acquisitions of both Predictive Therapeutics, LLC, Predictive Biotech, Inc. and LifeCode Genetics, Inc. has a number of patents and licenses agreements (notes to the "Financial Statements" has a complete list).

Predictive Technology Group, Inc. owns 10.12% (approx.) of Juneau Biosciences, LLC which came about through the aforementioned acquisition of LifeCode Genetics, Inc.

B. Date and State (or Jurisdiction) of Incorporation:

August 25, 2005 State of NEVADA

C. the issuer's primary and secondary SIC Codes;

Primary S.I.C- 2835

Secondary SIC- 8731

D. the issuer's fiscal year end date;

August 31

E. principal products or services, and their markets;

Predictive Technology Group, Inc. (PRED) has thru wholly owned subsidiaries, Predictive Therapeutics, LLC ("PRx"), Predictive Biotech, Inc. and LifeCode Genetics, is organized to develop, commercialize, acquire and invest in technologies involved in novel molecular diagnostic and therapeutic products in healthcare.

The PRx and Predictive Biotech subsidiaries intend to revolutionize the treatment of serious, chronic and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. PRx and Predictive Biotech have developed and/or acquired a pipeline of products. These proprietary technologies can open a window into the origin of human disease and the role that genes and their related proteins play in the disease's onset and progression. PRx uses genetic information as the cornerstone in the development of new diagnostics that assess a person's risk of disease and therapeutic products designed to effectively prevent and treat the disease.

The LifeCode Genetics, Inc. wholly owned subsidiary develops and commercializes gene based diagnostics treatments and therapies.

7) Describe the Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have

complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

Corporate Office-Predictive Therapeutics: 2749 East Parleys Way, Suite 101, Salt Lake City, UT 84109, $5,000.00 per month, on a month to month lease, includes administrative offices, lab space, lab benches and lab equipment.

8) Officers, Directors, and Control Persons

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant shareholders.

A. Names of Officers, Directors, and Control Persons. In responding to this item, please provide the names of each of the issuer's executive officers, directors, general partners and control persons (control persons are beneficial owners of more than five percent (5%) of any class of the issuer's equity securities), as of the date of this information statement.

Mr. Merle Ferguson is Chairman and Secretary

Mr. Bradley Robinson is President / Director

B. Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

   None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

   None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

   None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

   None

C. Beneficial Shareholders. Provide a list of the name, address and shareholdings or the percentage of shares owned by all persons beneficially owning more than ten percent (10%) of any class of the issuer's equity securities. If any of the beneficial shareholders are corporate shareholders, provide the name and address of the

person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders.

None

9) Third Party Providers

Please provide the name, address, telephone number, and email address of each of the following outside providers that advise your company on matters relating to operations, business development and disclosure:

Legal Counsel
Name: **Vern Norviel**
Firm: **Wilson Sonsini Goodrich & Rosati**
Address 1**: 650 Page Mill Road**
Address 2: **Palo Alto, CA 94304-1050**
Phone: 650-493-9300
Email: vnorniel@wsgr.com

Accountant or Auditor
Name: **STEVENSON & COMPNAY, CPAs**

Firm: **STEVENSON & COMPANY, CPAs**

Address 1: **12421 N. Florida Ave, Ste. 113**
Address 2: Tampa, FL 33612
Phone: 813-443-0619
Email: _____

Investor Relations Consultant
Name: Richard Kaiser
Firm: YES INTERNATIONAL
Address 1: 3419 Virginia Beach Blvd, Unit 252
Address 2: Virginia Beach, VA 23452
Phone: 7573066090
Email: rich@yesinternational.com

Other Advisor: Any other advisor(s) that assisted, advised, prepared or provided information with respect to this disclosure statement.
Name: _____
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

10) Issuer Certification

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles, but having the same responsibilities).

The certifications shall follow the format below:

I, Merle Ferguson certify that:

1. I have reviewed this Quarterly disclosure document of Predictive Technology Group, Inc..;

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

12/14/2016

/s/ Merle Ferguson

Chairman/ Secretary / Treasurer